Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $255.65

Posted by Francis Steltz on Aug 14th, 2026

Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) have been given an average rating of “Moderate Buy” by the sixteen analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $255.6471.

A number of equities analysts recently issued reports on the company. Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research report on Monday. Royal Bank Of Canada increased their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Mizuho set a $264.00 target price on Charles River Laboratories International in a research note on Monday. Finally, CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a report on Monday, July 20th.

View Our Latest Stock Analysis on CRL

Insider Transactions at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 129,817 shares of company stock worth $31,774,935 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds have recently added to or reduced their stakes in CRL. Madison Asset Management LLC acquired a new position in Charles River Laboratories International during the 2nd quarter worth approximately $3,805,000. Great Lakes Advisors LLC acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at approximately $459,000. Trust Asset Management LLC acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at approximately $129,000. Handelsbanken Fonder AB boosted its stake in shares of Charles River Laboratories International by 36.9% in the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock valued at $4,378,000 after buying an additional 5,200 shares in the last quarter. Finally, Czech National Bank boosted its stake in shares of Charles River Laboratories International by 2.3% in the second quarter. Czech National Bank now owns 13,710 shares of the medical research company’s stock valued at $3,109,000 after buying an additional 307 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 0.9%

CRL stock opened at $281.78 on Tuesday. The company has a market cap of $13.45 billion, a price-to-earnings ratio of -58.10, a price-to-earnings-growth ratio of 2.95 and a beta of 1.38. The company has a fifty day moving average price of $222.90 and a 200 day moving average price of $190.70. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a 12 month low of $144.26 and a 12 month high of $288.02.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same period last year, the firm posted $3.12 EPS. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts expect that Charles River Laboratories International will post 11.35 earnings per share for the current year.

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.